stem cell clinic gilbert: clear help for joint soreness

Daily use can make an older joint sore

A worn or irritated joint often aches during daily use and after longer activity. It can feel stiff after sitting, then ease once you start moving again. Swelling can also make bending or reaching harder.

Where it hurts helps explain what may be sore. Pain deep in the joint can differ from a sore tendon, the tough band joining muscle to bone. That difference is one reason an exam matters.

Gentle movement can calm a mild flare

Rest the activity that caused the flare for a short time. Keep other comfortable movements in your day unless a clinician says otherwise. Comfortable movement can prevent extra stiffness while the flare settles.

Use warmth before moving if the joint feels tight. A cold pack may reduce swelling after activity. Ask your doctor which medicine is safe with your health and other drugs.

An exam helps when soreness keeps returning

Book an exam when soreness returns or limits your daily tasks. The clinician asks which movements hurt and when the ache started. Next comes a check of strength, motion, swelling, and tenderness.

The visit also covers your health history and prior care. QC Kinetix can discuss regenerative treatments, including PRP, which gathers blood parts that help stop bleeding into a shot given in or near the joint. The aim is to calm the ache and make daily motion easier, though results can differ. You'll hear which choices suit the exam and which ones don't.

Sources

1. FDA states in its consumer alert that the only FDA-approved stem cell products in the United States are blood-forming stem cells derived from umbilical cord blood, approved for disorders of the blood-forming system, and that NONE of these products - stem cells, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic fluid - has been approved for the treatment of any orthopedic condition, including osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain or shoulder pain.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. , 2020.

2. The 2018 AAOS/NIH consensus work group recommended that minimally manipulated mixed cell preparations be called CELL THERAPY rather than stem cell therapy, and that their untested and uncharacterised nature be clearly communicated to patients and the public, because stem cells have properties these preparations do not meet.

   Chu CR, et al. — Optimizing Clinical Use of Biologics in Orthopaedic Surgery: Consensus Recommendations From the 2018 AAOS/NIH U-13 Conference. J Am Acad Orthop Surg, 2019. DOI: 10.5435/JAAOS-D-18-00305.

3. A 2016 analysis of internet marketing found widespread direct-to-consumer promotion of unapproved stem cell interventions by businesses based in the United States - not only in countries with lax medical regulation - and concluded regulators must better oversee the marketplace.

   Turner L, et al. — Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry. Cell Stem Cell, 2016. DOI: 10.1016/j.stem.2016.06.007.

4. In a 480-patient, four-arm, multicenter randomized phase 2/3 trial, none of three orthobiologic cell injections - autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction, or allogeneic umbilical cord tissue-derived mesenchymal stromal cells - was superior to any other, or to a corticosteroid injection control, on pain at 12 months.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial. Nat Med, 2023. DOI: 10.1038/s41591-023-02632-w.

5. The OARSI non-surgical management guideline evaluated 60 interventions with GRADE methodology and built its recommendations around core treatments - structured exercise, weight management and self-management education - for every patient with knee osteoarthritis, regardless of what else is added.

   Bannuru RR, et al. — OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage, 2019. DOI: 10.1016/j.joca.2019.06.011.